Plasma β-amyloid peptide, transforming growth factor-β1, and risk for cerebral amyloid angiopathy

Steven M. Greenberg, Hyun Soon Cho, Heather C. O'Donnell, Jonathan Rosand, Alan Z. Segal, Linda H. Younkin, Steven G. Younkin, G. William Rebeck

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Despite the documented association between apolipoprotein E genotype and cerebral amyloid angiopathy (CAA), a substantial proportion of CAA-related hemorrhages occur in patients without known risks for this disorder. Two other factors implicated in the pathogenesis of CAA are the amyloid-β peptide (preferentially deposited in vessels as a 40-amino acid species) and the multifunctional cytokine transforming growth factor-β1 (a specific promoter of vascular amyloid deposition in transgenic models). We measured plasma concentrations of these factors in a series of 25 patients diagnosed with probable or definite CAA-related hemorrhage and compared them with 21 patients with hemorrhage due to probable hypertensive vasculopathy and 42 elderly control subjects without hemorrhage. We found no differences among the groups in concentrations of the 40- or 42-amino acid species of β-amyloid or either the active or latent form of transforming growth factor-β1. While the data do not exclude important roles for these molecules as risks for CAA, they indicate that plasma measurements are not useful in its diagnosis.

Original languageEnglish (US)
Pages (from-to)144-149
Number of pages6
JournalAnnals of the New York Academy of Sciences
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science


Dive into the research topics of 'Plasma β-amyloid peptide, transforming growth factor-β1, and risk for cerebral amyloid angiopathy'. Together they form a unique fingerprint.

Cite this